FFIS DKO 9, FFIS DKO B2M MICA cl9
The cell line is not validated yet.
RCPCMi007-A-4
General
iPSC Line |
|
| hPSCreg name | RCPCMi007-A-4 |
| Cite as: | RCPCMi007-A-4 |
| Alternative name(s) |
FFIS DKO 9, FFIS DKO B2M MICA cl9
|
| iPSC line type | Human induced pluripotent stem cell (hiPSC) |
| Similar iPSC lines | No similar lines found. |
| Last update | 7th September 2026 |
| User feedback | |
Provider |
|
| Generator | Federal State Budgetary Institution Federal Research and Clinical Center of Physical-Chemical Medicine of Federal Medical Biological Agency (RCPCM) |
| Owner | Federal State Budgetary Institution Federal Research and Clinical Center of Physical-Chemical Medicine of Federal Medical Biological Agency (RCPCM) |
| Distributors | |
| Derivation country | Russia |
External iPSC Databases |
|
| BioSamples | SAMEA123426021 |
General iPSC Information |
|
| * Is the cell line readily obtainable for third parties? |
Yes Research use: allowed
Clinical use: allowed
Commercial use: allowed
|
| Subclone of | |
iPSC Genetic Modification
| Genetic modifications not related to a disease |
|
Donor Information
General Donor Information |
|
| Sex | female |
Phenotype and Disease related information (Donor) |
|
| Diseases | No disease was diagnosed.
|
External Databases (Donor) |
|
| BioSamples | SAMEA8944452 |
Ethics
Also have a look at the ethics information for the parental line
RCPCMi007-A
.
| Is there an MTA available for the cell line? | No |
| For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used? | |
| Are you aware of any constraints on the use or distribution of the cell line from the owner or any parties identified in the query above? | No |
iPSC Derivation
General |
|
|
The source cell information can be found in the parental cell line
RCPCMi007-A.
|
|
| Passage number reprogrammed | 13 |
Reprogramming method |
|
| Vector type | Non-integrating |
| Vector | Sendai virus |
Vector free reprogramming |
|
| Type of used vector free reprogramming factor(s) |
None
|
Other |
|
| Selection criteria for clones | cloning on Tesr1 media for 4-5 passages. the main selection criterion morphology and stable karyotype |
| Derived under xeno-free conditions |
Yes |
| Derived under GMP? |
No |
| Available as clinical grade? |
No |
iPSC Culture Conditions
| Surface coating | Matrigel/Geltrex |
| Feeder cells |
No |
| Passage method |
Enzymatically
TrypLE
|
| O2 Concentration | 20 % |
| CO2 Concentration | 5 % |
| Medium |
mTeSR™ 1
|
| Has Rock inhibitor (Y27632) been used at passage previously with this iPSC line? | Yes |
| Has Rock inhibitor (Y27632) been used at cryo previously with this iPSC line? | Yes |
| Has Rock inhibitor (Y27632) been used at thaw previously with this iPSC line? | Yes |
iPSC Characterisation
Analysis of undifferentiated iPSCs
| Marker | Expressed | Immunostaining | RT-PCR | Flow Cytometry | Enzymatic Assay | Expression Profiles |
| DPPA-5 |
Yes |
|||||
| NANOG |
Yes |
|||||
| SALL-4 |
Yes |
|||||
| SOX2 |
Yes |
|
||||
| SSEA-4 |
Yes |
|||||
| TRA 1-60 |
Yes |
|||||
| POU5F1 (OCT-4) |
Yes |
Differentiation Potency
In vitro directed differentiation
Morphology
In vitro directed differentiation
Morphology
In vitro directed differentiation
Morphology
Microbiology / Virus Screening |
|
| Mycoplasma | Negative |
Genotyping
Karyotyping (iPSC Line) |
|
| Has the iPSC line karyotype been analysed? |
Yes
46XX
Passage number: 13
Karyotyping method:
G-Banding
|
Other Genotyping (iPSC Line) |
|
Login to share your feedback, experiences or results with the research community.